Emerging evidence supports the use of psilocybin in palliative care, yet Schedule I status uniquely limits access outside of clinical trials in the US.
Alyviah Paquette, BS Pharm, 2026 PharmD Candidate
Advertisement
Articles by Alyviah Paquette, BS Pharm, 2026 PharmD Candidate
Advertisement
Latest Updated Articles
Pathways to Psilocybin in Palliative CareMay 14th 2026
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19 in Adolescents and Adults
2
Why Some Patients Do Not Respond to GLP-1 Therapies
3
What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results
4
GIRE Combination Shows PFS Benefit in First-Line Metastatic Breast Cancer Treatment, Earning FDA Priority Review
5